Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan.
College of Medicine, Chang Gung University, Taoyuan, Taiwan.
PLoS One. 2020 Apr 8;15(4):e0231505. doi: 10.1371/journal.pone.0231505. eCollection 2020.
The mortality rate of patients on extracorporeal membrane oxygenation (ECMO), especially those patients that develop acute kidney injury (AKI) is high. Acute kidney disease (AKD) is a term used to describe the continuum from AKI to chronic kidney disease. However, the role of AKD in predicting the prognosis of patients on ECMO support is unclear.
A total of 168 patients who received ECMO support and survived for more than 7 days at a single hospital from 2003 to 2008 were enrolled for this study and followed up for 10 years or till mortality. Kaplan-Meier analysis and Cox proportional hazards model were used to determine the prognostic factors associated with survival.
The median survival times of patients with stage 0, stage 1, stage 2 and stage 3 AKD were ≥ 10 years, 43.9 months, 1 month, and half a month, respectively. There were statistically significant differences in cumulative survival rate between patients with stage 3 AKD and those with stage 0, 1, and 2 AKD (Cox-Mantel log rank test, p<0.001, p<0.001, p = 0.023), and between patients with stage 0 AKD and those with stage 1 and 2 AKD (Cox-Mantel log rank test, p = 0.012, p<0.001). Cox regression analysis revealed that AKD stage (hazard ratio [HR]: 2.576, 95% confidential interval [CI]: 1.268-5.234, p = 0.009 for stage 1; HR: 2.349; 95% CI: 1.101-5.512, p = 0.029 for stage 2; HR: 5.252; 95% CI: 2.715-10.163, p<0.001 for stage 3) was significant independent predictor of survival.
AKD stage is an independent predictor of survival in patients on ECMO support.
体外膜肺氧合(ECMO)患者,尤其是发生急性肾损伤(AKI)的患者,死亡率较高。急性肾脏病(AKD)是一个用来描述从 AKI 到慢性肾脏病的连续过程的术语。然而,AKD 在预测 ECMO 支持患者预后中的作用尚不清楚。
本研究纳入了 2003 年至 2008 年在一家医院接受 ECMO 支持并存活超过 7 天的 168 例患者,并进行了 10 年或直至死亡的随访。采用 Kaplan-Meier 分析和 Cox 比例风险模型确定与生存相关的预后因素。
AKD 0 期、1 期、2 期和 3 期患者的中位生存时间分别为≥10 年、43.9 个月、1 个月和半个月。AKD 3 期患者的累积生存率与 AKD 0 期、1 期和 2 期患者之间存在统计学差异(Cox-Mantel 对数秩检验,p<0.001,p<0.001,p=0.023),与 AKD 0 期患者与 AKD 1 期和 2 期患者之间也存在统计学差异(Cox-Mantel 对数秩检验,p=0.012,p<0.001)。Cox 回归分析显示,AKD 分期(危险比[HR]:2.576,95%置信区间[CI]:1.268-5.234,p=0.009 分期 1;HR:2.349;95%CI:1.101-5.512,p=0.029 分期 2;HR:5.252;95%CI:2.715-10.163,p<0.001 分期 3)是 ECMO 支持患者生存的独立显著预测因素。
AKD 分期是 ECMO 支持患者生存的独立预测因素。